Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162855

SCHEMBL10162855

SCHEMBL10162855

CC(=O)c1cc(CNC(=O)c2cc(C(=O)NCc3ccc4oc(=O)n(C)c4c3)nc3ccnn23)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 5/20 0.39
▸ ADAMTS4 O75173 2/20 0.39
▸ MMP3 P08254 2/20 0.39
▸ MMP8 P22894 2/20 0.39
▸ MMP12 P39900 1/20 0.39
▸ CACNA1G O43497 2/20 0.36
▸ CACNA1H O95180 2/20 0.36
▸ CACNA1I Q9P0X4 2/20 0.36
▸ METTL3 Q86U44 1/20 0.35
▸ METTL14 Q9HCE5 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPT P10636 4/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ TP53 P04637 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162857 0.94 MMP13 (0.39) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10208196 0.93 MMP13 (0.38) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8229564 0.92 CACNA1G (0.43) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8228615 0.90 MMP13 (0.50) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8226242 0.89 MAPK1 (0.41) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8225958 0.89 TP53 (0.44) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10163506 0.89 MMP13 (0.45) MMP13ADAMTS4MMP3CACNA1GCACNA1H
SCHEMBL10162842 0.89 MMP13 (0.41) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162862 0.88 TP53 (0.40) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8228662 0.88 MMP13 (0.39) MMP13ADAMTS4MMP3MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.